The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China; Guangdong Provincial Key Laboratory of Reproductive Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China; Guangdong Provincial Key Laboratory of Reproductive Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
Fertil Steril. 2019 May;111(5):928-935. doi: 10.1016/j.fertnstert.2019.01.017. Epub 2019 Mar 25.
To investigate whether aneuploidy screening in preimplantation genetic testing (PGT) for monogenic diseases improves the ongoing pregnancy/live birth rate of single frozen/thawed embryo transfer (FET) cycles in young women.
Retrospective cohort study.
Single university-based fertility center.
PATIENT(S): From January 2016 to December 2017, 569 FET cycles were selected for analysis. The aneuploidy screening (AS) group included 131 FET cycles from 105 oocyte retrieval cycles in 98 patients who underwent PGT for monogenic diseases with aneuploidy screening, and the non-AS group included 438 FET cycles from 280 oocyte retrieval cycles in 266 patients who underwent PGT for monogenic diseases without aneuploidy screening.
INTERVENTION(S): The patient population was all under the age of 35 years and underwent PGT for monogenic diseases with and without AS.
MAIN OUTCOME MEASURE(S): Ongoing pregnancy/live birth rate, live birth rate, implantation rate, and miscarriage rate.
RESULT(S): Aneuploidy screening significantly improved the ongoing pregnancy/live birth rate (61.22% vs. 43.98%), implantation rate (64.29% vs. 50.38%), and live birth rate (53.06% vs. 36.09%) of young women carrying monogenic diseases in the first FET cycles. When adjusted for the parity, number of previous miscarriages, and percentage of infertility, the likelihood of implantation was 1.874 times higher (95% confidence interval 1.126-3.119), and an ongoing pregnancy/live birth was 2.139 times more likely (95% confidence interval 1.295-3.534). In addition, the miscarriage rate was significantly decreased (3.17% vs. 11.94%). In the cumulative pregnancy outcomes, the cumulative ongoing pregnancy/live birth rate both per transfer and per patient were significantly higher in the AS group (62.24% vs. 50.38% and 79.59% vs. 68.80%), but no difference existed after adjusting for the parity, number of previous miscarriage, and percentage of infertility. Nevertheless, aneuploidy screening reduced the time interval from the first ET to the achievement a pregnancy.
CONCLUSION(S): Aneuploidy screening in PGT significantly improved the ongoing pregnancy/live birth rate of young women carrying monogenic diseases in the first FET cycles.
探讨胚胎植入前遗传学检测(PGT)中进行非整倍体筛查是否能提高年轻女性行单个冻融胚胎移植(FET)周期的持续妊娠/活产率。
回顾性队列研究。
单所大学附属医院的生殖中心。
2016 年 1 月至 2017 年 12 月,共选取了 569 个 FET 周期进行分析。非整倍体筛查(AS)组包括 131 个 FET 周期,来源于 98 例患者的 105 个卵母细胞采集周期,这些患者因单基因疾病行 PGT 并进行了 AS;非 AS 组包括 438 个 FET 周期,来源于 266 例患者的 280 个卵母细胞采集周期,这些患者因单基因疾病行 PGT 但未进行 AS。
患者均年龄<35 岁,因单基因疾病行 PGT 并进行或不进行 AS。
持续妊娠/活产率、活产率、种植率和流产率。
AS 组显著提高了携带单基因疾病的年轻女性首次 FET 周期的持续妊娠/活产率(61.22% vs. 43.98%)、种植率(64.29% vs. 50.38%)和活产率(53.06% vs. 36.09%)。调整了产次、既往流产次数和不孕比例后,种植的可能性增加了 1.874 倍(95%置信区间 1.126-3.119),持续妊娠/活产的可能性增加了 2.139 倍(95%置信区间 1.295-3.534)。此外,流产率显著降低(3.17% vs. 11.94%)。在累积妊娠结局中,AS 组的每移植和每位患者的累积持续妊娠/活产率均显著更高(62.24% vs. 50.38%和 79.59% vs. 68.80%),但调整产次、既往流产次数和不孕比例后无差异。然而,AS 降低了首次 ET 到妊娠实现的时间间隔。
PGT 中进行非整倍体筛查可显著提高携带单基因疾病的年轻女性首次 FET 周期的持续妊娠/活产率。